Eli Lilly’s blockbuster weight loss GLP-1 drug ZEPBOUND has received FDA approval to treat obstructive sleep apnea in adults with obesity, alongside diet and exercise. This marks the first FDA-approved medication for obstructive sleep apnea.
The approval adds a second indication for ZEPBOUND, following its initial authorization for obesity in November 2023. The drug’s active ingredient, tirzepatide, is also marketed at lower doses for Type 2 diabetes under the brand name MOUNJARO. The drug functions as a dual agonist of the GLP-1 and GIP receptors, which regulate insulin secretion and appetite suppression.
In addition to obesity and sleep apnea, Lilly is e...
